Latest Safety News

Spacetalk has inked a strategic MVNO deal with TPG Telecom, aiming to improve mobile service economics and accelerate subscriber growth as it shifts towards a software-led business model.

Racura Oncology has secured Bellberry HREC approval for its HARNESS-1 lung cancer trial, enabling expansion to additional Australian sites including Chris O’Brien Lifehouse and Austin Health, setting the stage for accelerated patient enrolment.

Telix Pharmaceuticals has gained FDA alignment to advance Part 2 of its ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration-resistant prostate cancer, setting the stage for U.S. enrolment pending regulatory approval.

Island Pharmaceuticals has strengthened its intellectual property portfolio with a Singapore patent covering ISLA-101 for flavivirus infections, including Dengue and Chikungunya, extending commercial exclusivity to 2034 in a key Asia-Pacific market.

Neurotech International has received Notices of Allowance from the USPTO for two patents covering its lead drug NTI164, reinforcing its intellectual property position as it advances Phase 3 trials for autism spectrum disorder.

Qoria Limited and Aura Consolidated Group have fixed the exchange ratio for their proposed merger, with shareholders to receive one Aura CDI for every 17.32 Qoria shares. Aura’s US$100 million capital raise values Qoria shares at A$0.40 each, positioning Qoria shareholders to hold nearly a third of the merged entity.

SRJ Technologies has started delivering services under two major Middle East contracts, marking the transition from agreements to revenue-generating operations with AD Ports Group’s Divetech and Dubai Petroleum.

Imugene reports a second complete response in its Phase 1b trial of azer-cel combined with BTK inhibitors, including the first patient with Mantle Cell Lymphoma who had failed prior BTKi therapy.

Strategic Elements has achieved a significant milestone with the granting of a patent in Japan for its Energy Ink™ moisture energy platform, reinforcing its foothold in a critical electronics market and advancing its battery-free device ambitions.

Chimeric Therapeutics has appointed Hawkesbury Partners to lead a strategic review aimed at exploring options to enhance shareholder value, reflecting concerns that its market cap undervalues its clinical assets and infrastructure.

RocketDNA has fully deployed its Skylink® Operating System to all enterprise customers, driving over 1,000 active users and securing a 12-month pipeline of 25,000 pre-scheduled drone missions.

Imugene Limited reports a complete response in the first patient treated with azer-cel combined with BTK inhibitors in its Phase 1b trial, highlighting potential for resistant follicular lymphoma.